NCT03622788View on ClinicalTrials.gov

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAplastic AnemiaBone Marrow FailureChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveFollicular LymphomaHodgkin LymphomaMantle Cell LymphomaMyelodysplastic SyndromeMyeloproliferative NeoplasmNon-Hodgkin LymphomaPlasma Cell Myeloma
Interventions
BIOLOGICAL

Anti-Thymocyte Globulin

Given IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Cytokine-treated Veto Cells

Given IV

DRUG

Fludarabine

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo PBSCT

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER